AETHLON MEDICAL INC (AEMD Q3 FY2025 earnings call

Key Points

• Jim Frakes focused the company on oncology and reducing operating expenses.
• Steven LaRosa provided an update on the Australian Oncology trial: 3 patients enrolled, 2 didn't advance to treatment, 1 completed Hemopurifier treatment with no issues; protocol amended to improve enrollment speed, reduce screen failures, etc., and approved at sites. Progress in India trial with HREC approval at Medanta Medicity Hospital, awaiting CDSCO approval. Monitoring of bird flu, Marburg, and Ebola viruses.
• Financials: Cash balance ~$4.8 million as of Dec 31, 2024. Operating expenses decreased to $1.8 million in Q3 2025 from $3.6 million in Q3 2023, driven by reductions in payroll, professional fees, and G&A, partially offset by increased clinical trial expenses.

No detailed product segment financial performance with revenue contribution % provided in the transcript.

Forward-Looking

• G&A expenses may increase as clinical trials in Australia and India progress.
• May need to add a few people as the trials advance.

Risks

• Forward-looking statements subject to significant risks and uncertainties, including regulatory changes, trial outcomes not meeting expectations, and evolving virus situations as detailed in the company's filings.

Q: Details on first three patients in the study, protocol impact on India trial, clinical trial expense tax rebate.

A: Steven LaRosa explained about patient enrollment, Jim Frakes discussed the tax rebate for Australian clinical trials being an annual submission.

Q: Site activation and patient enrollment pace.

A: Steven LaRosa said the third site in Sydney will be active soon, expecting enrollment pace to accelerate.

Q: Bird flu treatment and expense run rate.

A: Jim Frakes discussed bird flu treatment status and expected increase in G&A expenses as trials progress